Barnard Katharine D, Venkat Manu V, Close Kelly, Heinemann Lutz, Weissberg-Benchell Jill, Hood Korey K, Kubiak Thomas, Kowalski Aaron J, Laffel Lori
Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK
Close Concerns, San Francisco, CA, USA.
J Diabetes Sci Technol. 2015 Jul;9(4):925-8. doi: 10.1177/1932296815588332. Epub 2015 Jun 17.
Diabetes technology is a cornerstone of diabetes management in the 21st century, with advances in available devices over recent years playing a central role in the way that health care has progressed. Psychosocial interventions have been shown to have a positive impact on glycemic control, reduce psychological distress and reduce costs of health care. Addressing and improving psychosocial outcomes that complement biomedical improvements and looking to the future are crucial to enhance patient acceptance of artificial pancreas (AP) systems.
To achieve closer collaboration and comparability across different AP research trials, a working group was established.
Existing measures fail to adequately capture the extent to which human and psychological factors play a role in the uptake and efficient use of AP systems. Understanding these factors will ultimately lead to the most benefit for users. Reliable measures of the psychosocial impact of AP systems for users is crucial to ensure that (1) regulatory authorities are able to robustly consider these aspects as part of their approval process, (2) government and private payers are able to factor these aspects into their decisions regarding reimbursement, and (3) persons with diabetes maximize benefits in terms of both glycemic control and quality of life to minimize the burden of diabetes in everyday life.
This working group will serve as a platform to foster exchange, identify research needs, and guide and initiate collaborative research laying the groundwork for optimal utilization of diabetes technology in clinical diabetes care. A close collaboration among all key stakeholders is crucial to ensure that devices are designed, trialed, approved, and provided with minimal user burden and maximum beneficial effect.
糖尿病技术是21世纪糖尿病管理的基石，近年来可用设备的进步在医疗保健的发展方式中发挥了核心作用。心理社会干预已被证明对血糖控制有积极影响，可减轻心理困扰并降低医疗保健成本。解决并改善补充生物医学改善的心理社会结果并展望未来对于提高患者对人工胰腺（AP）系统的接受度至关重要。
为了在不同的AP研究试验中实现更紧密的合作和可比性，成立了一个工作组。
现有措施未能充分捕捉人类和心理因素在AP系统的采用和有效使用中所起作用的程度。了解这些因素最终将为用户带来最大利益。对用户而言，可靠衡量AP系统的心理社会影响对于确保以下几点至关重要：（1）监管机构能够在其审批过程中充分考虑这些方面；（2）政府和私人支付方能够在其报销决策中考虑这些方面；（3）糖尿病患者在血糖控制和生活质量方面实现最大获益，以减轻日常生活中的糖尿病负担。
该工作组将作为一个平台，促进交流、确定研究需求，并指导和启动合作研究，为在临床糖尿病护理中最佳利用糖尿病技术奠定基础。所有关键利益相关者之间的密切合作对于确保设备的设计、试验、审批和提供过程中用户负担最小且效益最大至关重要。
